News

Two Al algorithms from Anumana received FDA (US Food and Drug Administration) clearance in early2026 for something a standard 12-lead ECG has never been validated…

'Golden Years': Changing the story of ATTR-CMATTR-cardiac amyloidosis (ATTR-CM) is a progressive heart condition often mistaken for normal aging. For years,…

Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, announced…

AccurKardia said it was granted a U.S. patent for its machine-learning-based algorithm that can identify cardiac amyloidosis from a standard 12-lead ECG. Use of ECG…

In people with transthyretin amyloid cardiomyopathy (ATTR-CM), the buildup of faulty transthyretin (TTR) protein in the heart may contribute to blood clots that…

At the European Society of Cardiology's Heart Failure Congress in Barcelona, ​​Bayer announced the results of new analyses of acoramidis in transthyretin amyloid…

AbstractBackground: The care of patients with transthyretin amyloid cardiomyopathy (ATTR-CM) is often fragmented and routine datasets rarely capture real-world…

NAPLES, Fla., June 04, 2026 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives…

It has been a busy period for the amyloidosis treatment field. In April, Danish drugmaker Novo Nordisk (NOV: N) received US Food and Drug Administration (FDA) Fast…

Transthyretin cardiac amyloidosis (ATTR-CM) is an increasingly recognized cause of heart failure and conduction disease in older adults. Resulting from either…